MedTrace Logo

Pancytopenia Related to PARP Inhibitors (PancytoRIB)

NCT04774627 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2021-09-23

No results posted yet for this study

Summary

Although PARP inhibitors (PARPi) have proved effective in treating many cancers, few patients receiving PARPi may experience rare but serious adverse events such as pancytopenia. Today, data about pancytopenia are scarce.

The objective was to investigate reports of pancytopenia adverse events related to PARPi, including olaparib, rucaparib, niraparib, talazoparib, veliparib and pamiparib using the World Health Organization's (WHO) pharmacovigilance database: VigiBase.

Conditions

Interventions

DRUG

PARP inhibitor

All patients treated at least with 1 PARPi

Sponsors & Collaborators

  • University Hospital, Caen

    lead OTHER

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-02-07
Primary Completion
2021-02-27
Completion
2021-03-24
FDA Drug
Yes

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04774627 on ClinicalTrials.gov